Feksofenadin Cipla 120 mg Norge - norsk - Statens legemiddelverk

feksofenadin cipla 120 mg

cipla europe nv - feksofenadinhydroklorid - tablett, filmdrasjert - 120 mg

Feksofenadin Cipla 180 mg Norge - norsk - Statens legemiddelverk

feksofenadin cipla 180 mg

cipla europe nv - feksofenadinhydroklorid - tablett, filmdrasjert - 180 mg

Altifex 120 mg Norge - norsk - Statens legemiddelverk

altifex 120 mg

orifarm generics (3) - feksofenadinhydroklorid - tablett, filmdrasjert - 120 mg

Telfast 180 mg Norge - norsk - Statens legemiddelverk

telfast 180 mg

opella healthcare france sas - feksofenadinhydroklorid - tablett, filmdrasjert - 180 mg

Telfast 120 mg Norge - norsk - Statens legemiddelverk

telfast 120 mg

opella healthcare france sas - feksofenadinhydroklorid - tablett, filmdrasjert - 120 mg

Hypericum STADA - Norge - norsk - Statens legemiddelverk

hypericum stada -

stada arzneimittel ag - prikkperikum - kapsel, hard

Rimactazid 150 mg / 75 mg Norge - norsk - Statens legemiddelverk

rimactazid 150 mg / 75 mg

sandoz - københavn - rifampicin / isoniazid - tablett, filmdrasjert - 150 mg / 75 mg

Rimstar Norge - norsk - Statens legemiddelverk

rimstar

sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg

Orkambi Den europeiske union - norsk - EMA (European Medicines Agency)

orkambi

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cystisk fibrose - andre åndedrettsprodukter - orkambi tabletter er angitt for behandling av cystisk fibrose (cf) hos pasienter i alderen 6 år og eldre som er homozygote for f508del-mutasjon i cftr-genet. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Cabometyx Den europeiske union - norsk - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.